Less-toxic therapy boosts NSCLC survival

Increased availability of better systemic chemo and targeted therapies for patients with advanced non-small cell lung cancer (NSCLC) is leading to increased overall survival, according to a 10-year Canadian study.

Researchers from the British Columbia Cancer Agency in Vancouver performed a retrospective chart review of all patients referred to the agency with advanced stage (IIIB or IV) lung cancer and grouped the patients into four one-year time frame cohorts.

One was termed "baseline" and the other three started six months after a new second-line agent (docetaxel, erlotinib and